80 FR 25308 - Center for Scientific Review; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 80, Issue 85 (May 4, 2015)

Page Range		25308-25308
FR Document		2015-10272

Federal Register, Volume 80 Issue 85 (Monday, May 4, 2015)

[Federal Register Volume 80, Number 85 (Monday, May 4, 2015)]
[Notices]
[Page 25308]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-10272]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; PAR-12-095: Special Review.
    Date: May 6, 2015.
    Time: 11:00 a.m. to 12:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892, (Telephone Conference Call).
    Contact Person: Angela Y. Ng, Ph.D., MBA, Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 6200, MSC 7804, Bethesda, MD 
20892, 301-435-1715, [email protected].

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)


    Dated: April 28, 2015.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-10272 Filed 5-1-15; 8:45 am]
 BILLING CODE 4140-01P

25308 Federal Register / Vol. 80, No. 85 / Monday, May 4, 2015 / Notices

ACTION: Notice. Inventors: Christophe R. Marchand, Dated: April 27, 2015.
Likun An, Yves G. Pommier (all of NCI) Richard U. Rodriguez,
SUMMARY: The inventions listed below
are owned by an agency of the U.S. Intellectual Property: HHS Reference Acting Director, Office of Technology
Government and are available for No. E–275–2014/0—US Provisional Transfer, National Institutes of Health.
licensing in the U.S. in accordance with Application No. 62/100,968 filed [FR Doc. 2015–10275 Filed 5–1–15; 8:45 am]
35 U.S.C. 209 and 37 CFR part 404 to January 8, 2015 BILLING CODE 4140–01–P
achieve expeditious commercialization Licensing Contact: Kevin Chang,
of results of federally-funded research Ph.D.; 301–435–5018; changke@
and development. Foreign patent mail.nih.gov DEPARTMENT OF HEALTH AND
applications are filed on selected Transgenic Mouse Model of Human HUMAN SERVICES
inventions to extend market coverage Open Angle Glaucoma
for companies and may also be available National Institutes of Health
for licensing. Description of Technology: Glaucoma
FOR FURTHER INFORMATION CONTACT: is a group of chronic neurodegenerative Center for Scientific Review; Notice of
Licensing information and copies of the disorders, which is characterized by Closed Meeting
U.S. patent applications listed below progressive loss of retinal ganglion cells
(RGC) and results in irreversible damage Pursuant to section 10(d) of the
may be obtained by writing to the
indicated licensing contact at the Office to optic nerve and thereby loss of vision. Federal Advisory Committee Act, as
of Technology Transfer, National Primary open angle glaucoma (POAG) is amended (5 U.S.C. App.), notice is
Institutes of Health, 6011 Executive the most common form of glaucoma; hereby given of the following meeting.
Boulevard, Suite 325, Rockville, mutations in MYOC gene are the most The meeting will be closed to the
Maryland 20852–3804; telephone: 301– common genetically defined cause of public in accordance with the
496–7057; fax: 301–402–0220. A signed POAG. As such, MYOC transgenic provisions set forth in sections
Confidential Disclosure Agreement will mouse models are very useful to study 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
be required to receive copies of the MYOC-associated glaucoma and to as amended. The grant applications and
patent applications. develop therapies to treat these diseases. the discussions could disclose
SUPPLEMENTARY INFORMATION: The NIH inventors generated a new confidential trade secrets or commercial
Technology descriptions follow. MYOC mouse model carrying a mutant property such as patentable material,
human MYOC (Y437H) gene. The and personal information concerning
Novel Furoquinolinediones as
Y437H mutation is associated with a individuals associated with the grant
Inhibitors of TDP2 and Their Potential
severe form of glaucoma among the applications, the disclosure of which
Use to Treat Cancer
identified MYOC mutations. would constitute a clearly unwarranted
Description of Technology: The Potential Commercial Applications:
invention relates to novel invasion of personal privacy.
• Research tools
Furoquinolinediones derivatives and Name of Committee: Center for Scientific
their ability to inhibit the enzyme • Drug development for glaucoma Review Special Emphasis Panel; PAR–12–
tyrosyl-DNA phosphodiesterase 2 Competitive Advantages: The new 095: Special Review.
(TDP2), and therefore to serve as anti- transgenic mouse model carries a Date: May 6, 2015.
cancer agents. Furthermore, these mutation associated with a severe form Time: 11:00 a.m. to 12:00 p.m.
compounds can be used in combination of glaucoma in humans. Agenda: To review and evaluate grant
with topoisomerase II (Top2) inhibitors, Development Stage: Prototype. applications.
such as etoposide or doxorubicin, to Place: National Institutes of Health, 6701
Inventors: Stanislav Tomarev (NEI),
more effectively kill cancer cells in a Rockledge Drive, Bethesda, MD 20892,
Yu Zhou (former NEI), Oleg Grinchuk
synergistic fashion. (Telephone Conference Call).
(former NEI).
Pharmaceutical compositions Contact Person: Angela Y. Ng, Ph.D., MBA,
Publications: Scientific Review Officer, Center for
containing these novel
Furoquinolinediones and methods of 1. Zhou Y, et al. Transgenic mice Scientific Review, National Institutes of
treatment comprising administering of expressing the Tyr437His mutant of human Health, 6701 Rockledge Drive, Room 6200,
such compositions are disclosed in the myocilin protein develop glaucoma. Invest MSC 7804, Bethesda, MD 20892, 301–435–
Ophthalmol Vis Sci. 2008 May;49(5):1932–9. 1715, nga@csr.nih.gov.
invention. [PMID 18436825]
Potential Commercial Applications: 2. Joe MK, Tomarev SI. Expression of
This notice is being published less than 15
Furoquinolinediones derivatives can myocilin mutants sensitizes cells to oxidative days prior to the meeting due to the timing
potentially be utilized for cancer stress-induced apoptosis: implication for limitations imposed by the review and
treatment either as stand alone or in glaucoma pathogenesis. Am J Pathol. 2010 funding cycle.
combination with other drugs such as Jun;176(6):2880–90. [PMID 20382707] (Catalogue of Federal Domestic Assistance
Top2 inhibitors. 3. Chou TH, et al. Transgenic mice Program Nos. 93.306, Comparative Medicine;
Competitive Advantages: expressing mutated Tyr437His human 93.333, Clinical Research, 93.306, 93.333,
Combination therapies based on the myocilin develop progressive loss ofretinal 93.337, 93.393–93.396, 93.837–93.844,
association of a TDP2 and a Top2 ganglion cell electrical responsiveness and
93.846–93.878, 93.892, 93.893, National
axonopathy with normal IOP. Invest
inhibitor because of their synergistic Institutes of Health, HHS)
Ophthalmol Vis Sci. 2014 Aug
mstockstill on DSK4VPTVN1PROD with NOTICES

effect should allow the decrease of the 14;55(9):5602–9. [PMID 25125600]
effective dosage. Their therapeutic Dated: April 28, 2015.
benefit should be observed at non-toxic Intellectual Property: HHS Reference Michelle Trout,
concentrations for normal cells as it has No. E–091–2015/0—Research Tool.
Program Analyst, Office of Federal Advisory
already been demonstrated for PARP Patent protection is not being pursued Committee Policy.
inhibitors in BRCA-deficient tumors. for this technology.
[FR Doc. 2015–10272 Filed 5–1–15; 8:45 am]
Development Stage: In vitro data Licensing Contact: Tedd Fenn; 424–
BILLING CODE 4140–01P
available 297–0336; tedd.fenn@nih.gov.

VerDate Sep<11>2014 19:40 May 01, 2015 Jkt 235001 PO 00000 Frm 00035 Fmt 4703 Sfmt 9990 E:\FR\FM\04MYN1.SGM 04MYN1

Document Created: 2018-02-21 10:22:41
Document Modified: 2018-02-21 10:22:41

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		May 6, 2015.
FR Citation		80 FR 25308

80 FR 25308 - Center for Scientific Review; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 80, Issue 85 (May 4, 2015)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health